Business
IB Announces Completion of Phase 1 Trial of GaM
Imaging Biometrics Limited has successfully completed its Phase 1 clinical trial for oral gallium maltolate (GaM) in recurrent glioblastoma, meeting all safety, tolerability, and pharmacokinetic objectives with no significant adverse events observed in the 26 enrolled patients, 22 of whom were included in a preliminary efficacy assessment. The trial demonstrated GaM's favorable safety profile and potential clinical benefit, encouraging the company to initiate a Phase 2 trial to further evaluate its efficacy. Disclaimer*
About this update from Imaging Biometrics Limited
[{"type":"text","content":"\n\nImaging Biometrics, Ltd\n(the \"Company\")\n \nImaging Biometrics Announces Successful Completion of Phase 1 Trial of Gallium Maltolate in Recurrent Glioblastoma\n \nImaging Biometrics, LLC, (\"IB\"), a leader in advanced quantitative imaging solutions, today announces the successful completion of its Phase 1 clinical trial evaluating oral gallium maltolate (GaM) for the treatment of recurrent or relapsed glioblastoma (GBM) - a major milestone in the company's oncology development program.\n \nFollowing comprehensive internal reviews conducted by the Medical College of Wisconsin (MCW), the trial met all predefined Phase 1 objectives, including safety, tolerability, and pharmacokinetic benchmarks. Importantly, significant adverse events were not observed, underscoring GaM's favorable safety profile.\n \n\"This achievement marks a pivotal step forward in our mission to bring novel, mechanism-driven therapies to patients with GBM,\" said Trevor Brown, CEO of Imaging Biometrics Ltd. \"We are encouraged by the data and the continued treatment of one long-standing patient, which speaks to GaM's potential clinical benefit. We look forward to sharing the full summary analysis soon.\"\n \nThe trial, led by Dr. Jennifer Connelly, MD (Principal Investigator) and Dr. Christopher Chitambar, MD (Co-Principal Investigator and Study Chair), enrolled 26 patients in a dose-escalation design. Of these, 24 were evaluable for toxicity, with 22 included in a preliminary efficacy assessment. All patients tolerated GaM exceptionally well, with no reported toxicities.\n \nOral GaM is a novel therapeutic candidate that targets tumor metabolism and iron-dependent cancer growth. Preclinical studies suggest its unique mechanism of action may synergize with existing treatment modalities, offering a promising new avenue for GBM therapy.\n \nWith Phase 1 now complete, IB is actively engaging with leading cancer centers to initiate a Phase 2 trial aimed at further evaluating GaM's efficacy and expanding its clinical footprint.\n \n--ENDS-\n \nThe Directors of the Company accept responsibility for the contents of this announcement.\n \nFor further information, please contact:\n \n\n\n\n\nIB Ltd\nTrevor Brown/Dr Al Musella/Brett Skelly/Michael Schmainda\nTel: 020 7469 0930\n\n\n\n\nAlbR Capital Limited (B...